Showing results (1441-1450 of 1,520) with videos related to

Sort By:
Pageof 152
Leukemia|October 19, 2011
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severityL Grkovic, K Baird, S M Steinberg, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancerHoussein Abdul Sater, Jennifer L Marté, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|February 8, 2023
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancerCecilia Monge, Changqing Xie, Yuta Myojin, et al.
Blood Advances|January 4, 2018
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myelomaSham Mailankody, Dickran Kazandjian, Neha Korde, et al.
Cancer Immunology, Immunotherapy : CII|March 21, 2025
PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancerCharalampos S Floudas, Meghali Goswami, Renee N Donahue, et al.
Blood Advances|April 26, 2024
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease preventionNoa G Holtzman, Lauren M Curtis, Rachel B Salit, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2006
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantationDaniel H Fowler, Jeanne Odom, Seth M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanomaMark E Dudley, Colin A Gross, Robert P T Somerville, et al.
Cancer Immunology, Immunotherapy : CII|November 6, 2009
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerJames L Gulley, Philip M Arlen, Ravi A Madan, et al.
Sarcoma|November 16, 2017
SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath TumorsChristine S Higham, Seth M Steinberg, Eva Dombi, et al.
Pageof 152